Phase 2 N=43 Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
Head And Neck Cancer
Primary: 12-Week Progression-Free Survival (PFS) — 48.57 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=65 Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Tolerability of Rituximab, Cyclophosphamide and Fludarabine in Patients With Previously Untreated CLL/SLL — 42 participants
Phase 2 N=39 A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
Pancreatic Cancer · Biliary Cancer
Primary: The Percentage of Untreated and Previously Treated Patients That Had a Partial Response to Treatment — 40; 7.1 percentage of patients
Phase 2 N=218 A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients
De Novo Kidney Transplantation
Primary: Percentage of Participants With Biopsy-confirmed Acute T-cell Mediated Rejection at Month 6 Assessed by Local Review — 6.7; 10.6 percentage of participants
Phase 2 N=11 Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy
Smoking Cessation
Primary: 7-day Point Prevalence Smoking Abstinence With Cotinine Validation at the End of Treatment — 0; 2 participants
Phase 2 N=20 A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)
Gastroparesis · Diabetes Mellitus
Primary: Venous Plasma Heme-oxygenase 1 (HO1) Protein Concentration — 1.6; 1.5; 10.6; 1.5 ng/mL — p=0.0002
Phase 2 N=20 Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).
TNF-receptor Associated Periodic Syndromes (TRAPS)
Primary: Percentage of Participants With Complete or Almost Complete Response at Day 15 — 95 Percentage of participants
Phase 2 N=16 Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Breast Cancer
Primary: Tolerability at One Year of Ovarian Function Suppression (OFS) Using Leuprolide and Letrozole. — 4 participants
Phase 2 N=52 Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
Non-alcoholic Fatty Liver Disease (NAFLD)
Primary: Change From Baseline in Percentage of Fat in the Liver as Assessed Using MRI at Week 24 — 0.00; -1.68; -2.89 Percentage of liver fat — p=0.3128
Phase 2 N=21 2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV A Bladder Cancer
Primary: Detection of Position Accuracy With Handheld Probe on Anatomical Location. — 35; 8; 2 lesions
Phase 2 N=30 Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
Hypoglycemia
Primary: Serious Adverse Events — 0; 0; 0 events
Phase 2 N=153 Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain
Dental Pain
Primary: Sum of Pain Intensity Difference From Baseline to 8 Hours — 6.016; 11.867; 11.282; 5.283 units on a scale — p=.4739
Phase 2 N=23 Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
Esophageal Cancer · Gastric Cancer
Primary: Overall Response Will be Characterized by the Patient's FDG-PET Scan — 11; 9 participants
Phase 2 N=39 Effects of Acipimox on Mitochondrial Function in Obesity
Abdominal Obesity · Insulin Resistance · Hypertriglyceridemia
Primary: Change From Baseline in Phosphocreatine Recovery (ViPCr) at 6-months — 1.7; 1.6 mM/s — p=0.97
Phase 2 N=40 Effects of Pioglitazone on Platelet Function
Diabetes · Platelet Function · Healthy
Primary: Percent Platelet Aggregation Induced by Arachidonic Acid — 80; 90; 60; 29 maximum percentage aggregation